We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PDL BioPharma (PDLI) Q3 Earnings Lag, Revenues Fall Y/Y
Read MoreHide Full Article
PDL BioPharma, Inc. (PDLI - Free Report) reported adjusted earnings of 11 cents per share in the third quarter of 2016, missing the Zacks Consensus Estimate of 14 cents. Adjusted arnings also declined from the year-ago figure of 49 cents. Nevertheless, the company’s shares gained 0.6% following its third-quarter earnings release.
The company generated total revenue of $53.6 million in the quarter, down 57% from the year-ago period.
Quarter in Detail
Revenues included royalties of $15 million from licensees to the Queen et al. patents, which consisted of royalties earned on third-quarter sales of Tysabri, net royalty payments from acquired royalty rights and a change in fair value of the royalty rights assets of 16 million, interest revenue of $8.6 million, product revenues of $14.1 million.
Revenues from the Queen et al. licenses were down 87.5% due to the expiration of the patent license agreement with Genentech, Inc. a subsidiary of Roche Holding AG (RHHBY - Free Report) .
The higher change in fair value was driven by an increase of $9.6 million in the fair value of Depomed royalty rights assets primarily due to a $5.0 million milestone payment based on the FDA approval of Invokamet XR, a type 2 diabetes drug in the Depomed portfolio.
Net cash royalty and milestone payments from acquired royalty rights amounted to $15.3 million in the third quarter, compared to $6.9 million in the year-ago period.
Research and development expense for the quarter came in at $1.9 million. This included research and development costs related to the completion of the pediatric trial on Tekturna by Noden, a global specialty pharmaceutical company. No R&D costs were recorded in the year-ago quarter.
General and administrative expenses were nearly $10.4 million, up 22.4% due to an increase in the headcount and expenses associated with the Noden-related product acquisitions.
The company’s board of directors has decided to eliminate the quarterly cash dividend payment in Aug 2016.
PDL BioPharma currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector include Anika Therapeutics Inc. (ANIK - Free Report) and Cambrex Corp. . Each of these stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Anika’s earnings estimates have increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company has posted a positive earnings surprise in all of the four trailing quarters with an average beat of 33.1%. Its share price has increased 9.4% year to date.
Cambrex’s earnings estimates have increased from $2.46 to $2.60 for 2016 and for 2017 estimates remained unchanged over the last 60 days. The company has posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19.8%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
PDL BioPharma (PDLI) Q3 Earnings Lag, Revenues Fall Y/Y
PDL BioPharma, Inc. (PDLI - Free Report) reported adjusted earnings of 11 cents per share in the third quarter of 2016, missing the Zacks Consensus Estimate of 14 cents. Adjusted arnings also declined from the year-ago figure of 49 cents. Nevertheless, the company’s shares gained 0.6% following its third-quarter earnings release.
The company generated total revenue of $53.6 million in the quarter, down 57% from the year-ago period.
Quarter in Detail
Revenues included royalties of $15 million from licensees to the Queen et al. patents, which consisted of royalties earned on third-quarter sales of Tysabri, net royalty payments from acquired royalty rights and a change in fair value of the royalty rights assets of 16 million, interest revenue of $8.6 million, product revenues of $14.1 million.
Revenues from the Queen et al. licenses were down 87.5% due to the expiration of the patent license agreement with Genentech, Inc. a subsidiary of Roche Holding AG (RHHBY - Free Report) .
The higher change in fair value was driven by an increase of $9.6 million in the fair value of Depomed royalty rights assets primarily due to a $5.0 million milestone payment based on the FDA approval of Invokamet XR, a type 2 diabetes drug in the Depomed portfolio.
Net cash royalty and milestone payments from acquired royalty rights amounted to $15.3 million in the third quarter, compared to $6.9 million in the year-ago period.
Research and development expense for the quarter came in at $1.9 million. This included research and development costs related to the completion of the pediatric trial on Tekturna by Noden, a global specialty pharmaceutical company. No R&D costs were recorded in the year-ago quarter.
General and administrative expenses were nearly $10.4 million, up 22.4% due to an increase in the headcount and expenses associated with the Noden-related product acquisitions.
The company’s board of directors has decided to eliminate the quarterly cash dividend payment in Aug 2016.
PDL BIOPHARMA Price, Consensus and EPS Surprise
PDL BIOPHARMA Price, Consensus and EPS Surprise | PDL BIOPHARMA Quote
Zacks Rank & Key Picks
PDL BioPharma currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector include Anika Therapeutics Inc. (ANIK - Free Report) and Cambrex Corp. . Each of these stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Anika’s earnings estimates have increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company has posted a positive earnings surprise in all of the four trailing quarters with an average beat of 33.1%. Its share price has increased 9.4% year to date.
Cambrex’s earnings estimates have increased from $2.46 to $2.60 for 2016 and for 2017 estimates remained unchanged over the last 60 days. The company has posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19.8%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>